Cargando…
Retraction Note: The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine
Autores principales: | Xie, Fang, Huang, Mei, Lin, Xiansheng, Liu, Chenhai, Liu, Zhen, Meng, Futao, Wang, Chao, Huang, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684641/ https://www.ncbi.nlm.nih.gov/pubmed/38017059 http://dx.doi.org/10.1038/s41598-023-48298-9 |
Ejemplares similares
-
The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine
por: Xie, Fang, et al.
Publicado: (2018) -
Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
por: Yao, Zhicheng, et al.
Publicado: (2022) -
BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2020) -
Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018) -
Retraction Note to: LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis
por: Huang, Fengting, et al.
Publicado: (2022)